A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

NCT03993132 · Completed

Last updated 2026-05-28

This study compared the effects of empagliflozin and GLP1 receptor agonists on serious heart-related outcomes in Danish adults with type 2 diabetes using their medical records.

Status Completed The study has finished.

Type Observational

Participants 26,774 people

Who can join Ages 18+ · all sexes

Timeline Started 2018-10 · est. completion 2022-06

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT03993132 ↗

Description as written by the study sponsor.

The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA).

Treatments tested

Empagliflozin Drug

new users (initiators) of Empagliflozin
Liraglutide Drug

initiators of Liraglutide

Main thing measured	Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - OT Analysis
Sponsor	Boehringer Ingelheim
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03993132 ↗